Physician profile
Michael Schowalter
NPI 1780028332
$4,372.58
in general payments reported to CMS, 2019-2025
32 companies · $725 in 2025
The $725 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $394 · 2021: $639 · 2022: $630 · 2023: $871 · 2024: $984 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,202 · Education: $378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,202.17 |
| Education | $377.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $952.93 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $416.32 | 2019-2025 | |
| Pfizer INC. | $279.07 | 2022-2025 | |
| Lilly USA, LLC | $244.20 | 2019-2025 | Ebglyss, Taltz |
| Sun Pharmaceutical Industries INC. | $220.40 | 2021-2025 | Winlevi, Ilumya |
| Ucb, INC. | $206.58 | 2020-2022 | |
| Abbvie INC. | $188.58 | 2019-2024 | Botox |
| Regeneron Healthcare Solutions, INC. | $183.09 | 2020-2024 | Libtayo |
| Vyne Pharmaceuticals INC. | $166.25 | 2021 | |
| Leo Pharma INC. | $152.14 | 2022-2024 | Adbry |
| Biofrontera INC. | $144.71 | 2020-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Dermira, INC. | $127.71 | 2019-2021 | |
| Galderma Laboratories, L.P. | $126.19 | 2020-2025 | Nemluvio |
| Incyte Corporation | $116.17 | 2022-2025 | Opzelura |
| Sanofi-Aventis U.S. LLC | $106.51 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $94.29 | 2023 | Evusheld |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.32 | 2022-2024 | Spevigo |
| E.R. Squibb & Sons, L.L.C. | $85.00 | 2022-2024 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $78.19 | 2019-2025 | Cabtreo, Siliq, Jublia |
| Genzyme Corporation | $64.57 | 2021-2022 | |
| Blueprint Medicines Corporation | $47.51 | 2023 | Ayvakit |
| Amgen INC. | $41.65 | 2024-2025 | Otezla, Otezla |
| Helsinn Therapeutics (U.S.), INC. | $37.08 | 2019-2020 | |
| Medimetriks Pharmaceuticals, INC. | $36.56 | 2020-2022 | |
| Journey Medical Corporation | $31.26 | 2024 | |
| Arcutis Biotherapeutics, INC. | $29.81 | 2023-2025 | Zoryve |
| Allergan, INC. | $27.30 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $25.69 | 2025 | Clear+Brilliant |
| Botanix Sb INC | $16.42 | 2025 | Sofdra |
| Leica Microsystems INC. | $13.30 | 2022 | |
| Kyowa Kirin, INC. | $13.09 | 2024 | Poteligeo |
| Mayne Pharma Commercial LLC | $11.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schowalter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.